Core Wealth Partners LLC Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Core Wealth Partners LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 18,323 shares of the biopharmaceutical company’s stock after purchasing an additional 159 shares during the period. Gilead Sciences comprises 1.0% of Core Wealth Partners LLC’s investment portfolio, making the stock its 25th largest position. Core Wealth Partners LLC’s holdings in Gilead Sciences were worth $1,692,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences during the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC grew its holdings in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

NASDAQ GILD opened at $107.89 on Wednesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business’s fifty day moving average is $104.35 and its 200 day moving average is $94.36. The company has a market capitalization of $134.36 billion, a PE ratio of 291.59, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.93%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of analyst reports. Wells Fargo & Company boosted their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Morgan Stanley boosted their target price on Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a report on Tuesday, March 11th. Oppenheimer raised their price target on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 4th. Royal Bank of Canada lifted their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.